Pfizer, the world's largest drug company, and Wyeth have sued Daiichi Sankyo-owned Ranbaxy Laboratories in a US court for infringing the patent rights of Wyeth's drug, Rapamune.
India's third largest network service provider, Reliance Communications (RCom), is close to signing an agreement with US-based GetJar to launch its own application store (app store, software modules to run specific tasks on own mobiles), sources said.
Elder Pharma employs about 3,300 people in India, with about 2,700 professionals in marketing and sales. This recruitment will help Elder Pharma to have one of the largest drug sales force in India, like market leaders such as Cipla, Ranbaxy, Piramal Healthcare and Lupin.
India Inc's order book doubled in the fourth quarter (January-March) of the last financial year compared, to the year-ago period.
CanvasM, a joint venture between Tech Mahindra and Motorola, is planning to launch 6,000 new indigenously developed applications for mobile phones.
Cephalon, a US-based drug maker, has filed a lawsuit against Lupin Ltd and its US subsidiary Lupin Pharmaceuticals for challenging the patents on its sleep disorder drug Nuvigil.
Andrew Witty, chief executive of GlaxoSmithKline (GSK), the world's second-largest drug company, was in India this week as part of the dedication of an albandazole manufacturing facility at Nashik to the World Health Organization (WHO)'s global programme to eliminate Lymphatic Filariasis.
The money, together with disinvestment proceeds, is crucial for Mukherjee to meet his fiscal deficit target of 5.5 per cent for 2010-11 from 6.7 per cent in 2009-10.
Plans to form JV for its data centre business
If most of the top 10 Indian drug companies were less than Rs 500-crore (Rs 5-billion) turnover ones a decade earlier and were focused only on domestic business, now they are companies with annual businesses ranging from Rs 2,000-Rs 6,000 crore (Rs 20-60 billion) and with operations spanning 60-100 countries and employing 3,000-5,000 people.
An analysis of the growth rate of 15 leading drug companies for the third quarter of 2008-09 show excellent performances in domestic turf have been often marred by the poor show of their acquired assets.
The deal size could be in excess of Rs 2,000 crore, though this could not be verified. Sivasankaran had invested close to Rs 1,800 crore in 2007 to take a 41 per cent stake in Aamby Valley. The Sahara Group is the majority investor, with a 51 per cent stake.
In this emerging trend, doctors are joining hands with venture capitalists, drug firms and medical equipment vendors to set up advanced medical care facilities at low costs.
This metro line would be a 33.65-km rail link between Bangalore City Centre and Bangalore International Airport.
It has 150 research and development locations in over 30 countries around the world, employing over 32,300 people.
the early 1980s, multinationals set up R&D units in India to make use of the low costs and huge talent pool.
In this emerging trend, doctors are joining hands with venture capitalists, drug firms and medical equipment vendors to set up advanced medical care facilities at low costs.
Mumbai-based Gammon Infrastructure wishes to buy stakes in international airport projects. The company is already in talks with companies that have won such projects in developing economies. "We expect the first such deal to close in six months," said Managing Director Parvez Umrigar.
Indian pharmaceutical companies, which are increasingly choosing to settle patent litigation with global drug majors in the US, would have to be more cautious now.
Anil Dhirubhai Ambani Group company Reliance Infrastructure (R-Infra) will soon be the official owner of the second phase of the Mumbai Metro project. The state government and the company will sign a concession agreement for the Rs 11,000-crore (Rs 110 billion) project on Thursday, according to sources.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances